The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: A phase I/II study.
G. S. Nowakowski
No relevant relationships to disclose
C. B. Reeder
Research Funding - Celgene
B. LaPlant
No relevant relationships to disclose
T. M. Habermann
No relevant relationships to disclose
C. Rivera
No relevant relationships to disclose
W. R. Macon
No relevant relationships to disclose
D. J. Inwards
No relevant relationships to disclose
I. N. M. Micallef
No relevant relationships to disclose
P. B. Johnston
No relevant relationships to disclose
L. F. Porrata
No relevant relationships to disclose
S. M. Ansell
No relevant relationships to disclose
T. E. Witzig
No relevant relationships to disclose